Immune Counter-Regulation in Melanoma Patients Vaccinated With GM-CSF
OBJECTIVES:
Primary
- To correlate circulating myeloid-derived suppressor cells (MDSC) and Treg frequencies
with clinical outcome.
Secondary
- To correlate circulating anti-sargramostim (GM-CSF) antibody levels with clinical
outcome.
OUTLINE: Archived peripheral blood mononuclear cells and serum samples are analyzed for
circulating myeloid-derived suppressor cells, Treg (CD3+/CD4+/CD25hi/FOXP3+) frequency, and
anti-sargramostim (anti-GM-CSF) antibody levels by flow cytometry and anti-GM-CSF
neutralizing antibody assay.
Observational
N/A
Overall and disease-free survival
No
Lisa Butterfield, PhD
Principal Investigator
University of Pittsburgh
Unspecified
CDR0000703098
NCT01388569
August 2011
Name | Location |
---|